Concentrations of 6-Thioguanine Nucleotide Correlate With Trough Levels of Infliximab in Patients With Inflammatory Bowel Disease on Combination Therapy-Reference-Cited by-同舟云学术

Concentrations of 6-Thioguanine Nucleotide Correlate With Trough Levels of Infliximab in Patients With Inflammatory Bowel Disease on Combination Therapy

Published:2015-06 Issue:6 Volume:13 Page:1118-1124.e3
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Yarur Andres J.,Kubiliun Maddie J.,Czul Frank,Sussman Daniel A.,Quintero Maria A.,Jain Anjali,Drake Katherine A.,Hauenstein Scott I.,Lockton Steven,Deshpande Amar R.,Barkin Jamie S.,Singh Sharat,Abreu Maria T.

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference30 articles.

1. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis;Ford;Am J Gastroenterol,2011

2. Infliximab, azathioprine, or combination therapy for Crohn's disease;Colombel;N Engl J Med,2010

3. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis;Panaccione;Gastroenterology,2014

4. Risk factors for opportunistic infections in patients with inflammatory bowel disease;Toruner;Gastroenterology,2008

5. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease;Kotlyar;Clin Gastroenterol Hepatol,2011

Cited by 148 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 6‐Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapy;Internal Medicine Journal;2024-09-05

2. Comparison of Endoscopic Healing and Durability between Combination Therapy with Infliximab and Azathioprine versus Infliximab Monotherapy in Pediatric Crohn's disease;2024-06-25

3. Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study;The Lancet Gastroenterology & Hepatology;2024-06

4. Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology;Therapeutic Drug Monitoring;2024-04-17

5. Therapeutic drug monitoring of vedolizumab therapy in inflammatory bowel disease;Journal of Gastroenterology and Hepatology;2024-02-21